Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 16/20 | 0.57 |
| ▸ | PPARG | P37231 | 2/20 | 0.55 |
| ▸ | PPARA | Q07869 | 2/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.51 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2301769 | 0.87 | PPARD (0.59) | PPARDPPARGPPARA | |
| SCHEMBL2300943 | 0.87 | ALDH1A1 (0.50) | PPARDPPARGPPARAPTPN1FFAR1 | |
| SCHEMBL14931854 | 0.77 | FFAR4 (0.47) | PPARDPPARGPPARAFFAR1 | |
| SCHEMBL12427069 | 0.76 | TRPV3 (0.45) | — | |
| SCHEMBL2111994 | 0.74 | PPARD (0.68) | PPARDPPARGPPARAPTPN1PTGDR2 | |
| SCHEMBL2304741 | 0.74 | PPARG (0.51) | PPARDPPARGPPARA | |
| SCHEMBL1549830 | 0.73 | PPARD (0.58) | PPARDPPARGPPARAFFAR1 | |
| SCHEMBL2298241 | 0.73 | FFAR1 (0.48) | PPARDPPARGFFAR1 | |
| SCHEMBL14436370 | 0.73 | PPARD (1.00) | PPARDPPARGPPARA | |
| SCHEMBL14931892 | 0.73 | POLB (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461183-B2 | PPAR agonist compounds, preparation and uses | GENFIT (FR) | 2013-06-11 | — | — | US | claimed |
| EP-2310371-B1 | PPAR AGONIST COMPOUNDS AND PREPARATION AND USES THEREOF FOR TREATING DIABETES AND/OR DYSLIPIDEMIA | GENFIT (FR) | 2013-05-15 | — | — | EP | claimed |
| US-20110195993-A1 | PPAR AGONIST COMPOUNDS, PREPARATION AND USES | GENFIT (FR) | 2011-08-11 | — | — | US | claimed |
| WO-2016149299-A1 | THERAPEUTIC COMPOUNDS THAT SUPPRESS PROTEIN ARGININE METHYLTRANSFERASE ACTIVITY FOR REDUCING TUMOR CELL PROLIFERATION | EPINOVA THERAPEUTICS CORP. (US) | 2016-09-22 | — | — | WO | disclosed |
| US-20160271149-A1 | THERAPEUTIC COMPOUNDS THAT SUPPRESS PROTEIN ARGININE METHYLTRANSFERASE ACTIVITY FOR REDUCING TUMOR CELL PROLIFERATION | EPINOVA THERAPEUTICS CORP. | 2016-09-22 | — | — | US | disclosed |
| US-8461183-B2 | PPAR agonist compounds, preparation and uses | GENFIT (FR) | 2013-06-11 | — | — | US | disclosed |
| EP-2310371-B1 | PPAR AGONIST COMPOUNDS AND PREPARATION AND USES THEREOF FOR TREATING DIABETES AND/OR DYSLIPIDEMIA | GENFIT (FR) | 2013-05-15 | — | — | EP | disclosed |
| US-20110195993-A1 | PPAR AGONIST COMPOUNDS, PREPARATION AND USES | GENFIT (FR) | 2011-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195993-A1 | PPAR AGONIST COMPOUNDS, PREPARATION AND USES | PPARD, PPARA, PPARG | PPARD 1/4885PPARG 3/4885PPARA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.